Vasopressin V2 Receptor Antagonist [EPC]

Known as: Vasopressin V2 Receptor Antagonist 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
0120152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
AIM The vasopressin V2 receptor antagonist tolvaptan has been used for the treatment of cirrhotic patients with ascites; however… (More)
Is this relevant?
Review
2016
Review
2016
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the… (More)
  • table 1
  • table 2
Is this relevant?
2015
2015
BACKGROUND A recent study showed that tolvaptan, a vasopressin V2 receptor antagonist, decreased total kidney volume (TKV) growth… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?